#United States #Sarasota #Organ-on-a-Chip #World Precision Instruments #TEER Technology

World Precision Instruments and SynVivo: A Breakthrough in Cell Monitoring

In a major leap forward for biomedical research, World Precision Instruments (WPI) has collaborated with SynVivo Inc. to launch an innovative multiplexed TEER-on-a-Chip platform. This advanced technology facilitates real-time cell monitoring within Organ-on-a-Chip (OOC) models, marking a significant advancement in the field of transepithelial electrical resistance (TEER) measurement.

The new EVOM™ Chip offers a remarkable capability for multiplexed TEER measurement across 12 channels, an advancement that promises to transform experimental workflows. WPI, a trusted name in TEER instrumentation for over three decades, merges its cutting-edge technology with SynVivo’s pre-integrated SynTEER™ models. This integration allows for continuous monitoring of cellular barriers directly within microfluidic devices, paving the way for enhanced reproducibility and precision in research.

The Importance of TEER Measurement

TEER measurement is a critical aspect of assessing the integrity of cellular barriers, typically utilized for studying drug delivery, barrier function assessment, and disease modeling. This innovative EVOM-Chip™ system enables researchers to track barrier formation and drug response in real-time, significantly elevating the throughput and accuracy of experimental data collection.

Gwen Fewell, President and CEO of SynVivo, emphasizes the collaboration's vital role in advancing functional barrier modeling. “By integrating TEER measurements directly into our chip technology, we are set to enhance data fidelity while minimizing variability. This not only streamlines workflows but also supports more predictive in vitro models,” Fewell noted.

Seamless Integration and Enhanced Workflow

The new platform allows for hands-free data collection that is fully compatible with live-cell imaging. Researchers can monitor cellular responses during various stages, from drug treatments to barrier formation, without compromising cell health. The platform has already been validated on the SynVivo SynBBB™ Blood-Brain Barrier model, where it demonstrated a solid correlation between electrical resistance and functional barrier properties, making it a pivotal tool for studies in CNS drug development and inflammation.

Mark Rutledge, CEO of WPI, highlighted the significance of addressing gaps related to standardization and automation in Organ-on-a-Chip technology. With the EVOM-Chip™, researchers can confidently analyze their platforms throughout the entire study phase, drastically improving the chances of producing reliable and reproducible results.

Looking Ahead: Applications in Drug Development

As the demand for OOC models expands rapidly, the challenges of standardization and automation are becoming increasingly critical. This collaboration signifies a strategic move to bridge those gaps. The initial application of TEER measurement on the SynBBB™ model indicates promising potential in broader research areas such as inflammation studies and neurovascular research. This expanded capability will ideally prompt pharmaceutical researchers to adopt the platform, helping preclinical models align closer to human clinical outcomes.

Live Demonstrations at MPS World Summit

To showcase the capabilities of the EVOM-Chip™ and SynTEER-on-Chip systems, WPI and SynVivo will host live demonstrations at the MPS World Summit in Brussels from June 10–13, 2025. Attendees can visit booth #131 for WPI and booth #404 for SynVivo to witness the technology in action and learn how integrated TEER-on-Chip technology could accelerate their research efforts.

Conclusion

As World Precision Instruments and SynVivo continue to innovate, the TEER-on-a-Chip platform stands as a testament to the ongoing evolution in biomedical research. Researchers now have a powerful tool at their disposal to uncover complex questions in drug development, paving the way for advancements in treatment and therapeutic strategies. With the merger of precision engineering and biological insights, the future of organ-on-a-chip technology looks more promising than ever.